Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CKPT Checkpoint Therapeutics	$4.26	$4.20	$2.00 ▼ $4.50	$370.71M	1.18	1.48 million shs	N/A
RNAC Cartesian Therapeutics	$10.39 -2.7%	$10.47	$8.46 ▼ $28.83	$277.19M	0.33	110,647 shs	51,193 shs
TECX Tectonic Therapeutic	$19.87 +0.4%	$21.26	$13.70 ▼ $61.07	$369.72M	3.26	183,100 shs	112,075 shs
VOR Vor Biopharma	$1.62 +52.8%	$0.38	$0.13 ▼ $1.80	$202.44M	-0.51	3.88 million shs	66.66 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CKPT Checkpoint Therapeutics	0.00%	0.00%	0.00%	+5.45%	+98.14%
RNAC Cartesian Therapeutics	-2.72%	+5.70%	+8.68%	-16.81%	-61.53%
TECX Tectonic Therapeutic	+0.35%	+5.97%	-7.62%	+17.99%	+20.64%
VOR Vor Biopharma	+52.83%	+458.62%	+710.41%	+161.29%	+62.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CKPT Checkpoint Therapeutics	0.577 of 5 stars	1.2	0.0	4.2	1.4	0.8	0.0
RNAC Cartesian Therapeutics	1.922 of 5 stars	3.4	0.0	0.0	2.7	3.3	0.0
TECX Tectonic Therapeutic	2.8761 of 5 stars	3.7	1.0	0.0	2.8	3.3	0.6
VOR Vor Biopharma	3.9476 of 5 stars	4.3	5.0	0.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CKPT Checkpoint Therapeutics	2.33	Hold	$4.33	1.72% Upside
RNAC Cartesian Therapeutics	2.71	Moderate Buy	$41.25	297.02% Upside
TECX Tectonic Therapeutic	3.33	Buy	$83.60	320.73% Upside
VOR Vor Biopharma	2.60	Moderate Buy	$5.63	247.44% Upside

Current Analyst Ratings Breakdown

Latest VOR, RNAC, CKPT, and TECX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$3.00
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform
6/11/2025	TECX Tectonic Therapeutic	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$76.00
6/6/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$87.00
6/5/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	TECX Tectonic Therapeutic	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$51.00 ➝ $85.00
5/9/2025	VOR Vor Biopharma	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	VOR Vor Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform	$6.00 ➝ $6.00
5/9/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
5/8/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$41.00 ➝ $40.00
5/8/2025	VOR Vor Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CKPT Checkpoint Therapeutics	$41K	9,041.59	N/A	N/A	($0.47) per share	-9.06
RNAC Cartesian Therapeutics	$38.91M	6.93	N/A	N/A	($0.27) per share	-38.48
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$9.54 per share	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CKPT Checkpoint Therapeutics	-$51.85M	-$1.29	N/A	∞	N/A	N/A	N/A	-659.07%	8/11/2025 (Estimated)
RNAC Cartesian Therapeutics	-$77.42M	-$52.83	N/A	N/A	N/A	-510.72%	N/A	-7.01%	8/6/2025 (Estimated)
TECX Tectonic Therapeutic	-$57.98M	-$7.31	N/A	N/A	N/A	N/A	-30.13%	-27.52%	8/13/2025 (Estimated)
VOR Vor Biopharma	N/A	-$1.51	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest VOR, RNAC, CKPT, and TECX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CKPT Checkpoint Therapeutics	-$0.10	-$0.19	-$0.09	-$0.19	$4.53 million	N/A
5/8/2025	Q1 2025	RNAC Cartesian Therapeutics	-$0.61	-$0.68	-$0.07	-$0.68	$0.69 million	$1.10 million
5/8/2025	Q1 2025	TECX Tectonic Therapeutic	-$1.10	-$0.93	+$0.17	-$0.93	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CKPT Checkpoint Therapeutics	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CKPT Checkpoint Therapeutics	N/A	0.29	0.29
RNAC Cartesian Therapeutics	N/A	12.34	12.34
TECX Tectonic Therapeutic	N/A	22.92	22.92
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CKPT Checkpoint Therapeutics	22.00%
RNAC Cartesian Therapeutics	86.95%
TECX Tectonic Therapeutic	62.63%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
CKPT Checkpoint Therapeutics	2.10%
RNAC Cartesian Therapeutics	60.30%
TECX Tectonic Therapeutic	9.20%
VOR Vor Biopharma	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CKPT Checkpoint Therapeutics	10	87.02 million	47.81 million	Optionable
RNAC Cartesian Therapeutics	64	25.95 million	10.30 million	Optionable
TECX Tectonic Therapeutic	120	18.67 million	16.96 million	N/A
VOR Vor Biopharma	140	124.96 million	65.45 million	Not Optionable

VOR, RNAC, CKPT, and TECX Headlines

Recent News About These Companies

HC Wainwright & Co. Upgrades Vor Biopharma (VOR)

June 30 at 9:53 PM | msn.com

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

June 30 at 2:31 PM | benzinga.com

Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why

June 30 at 11:41 AM | zacks.com

Vor Biopharma (NYSE:VOR) Upgraded at HC Wainwright

June 30 at 8:20 AM | marketbeat.com

Vor Biopharma (NYSE:VOR) Gains Momentum S&P 500

June 27, 2025 | kalkinemedia.comK

Vor Biopharma Inc. Stock Grades - Barron's

June 27, 2025 | barrons.com

Vor Biopharma (NYSE:VOR) Stock Price Expected to Rise, Robert W. Baird Analyst Says

June 27, 2025 | marketbeat.com

Vor, with new CEO, changes course to target autoimmune disease

June 26, 2025 | biopharmadive.comB

After axing 95% workforce, Vor bets $4B+ on Remegen’s telitacicept

June 26, 2025 | bioworld.comB

Vor Biopharma Insider Trading Activity | NASDAQ:VOR | Benzinga

June 26, 2025 | benzinga.com

Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions

June 26, 2025 | fiercepharma.comF

Vor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune Therapy

June 26, 2025 | msn.com

Vor Biopharma Target of Unusually High Options Trading (NYSE:VOR)

June 26, 2025 | marketbeat.com

Vor Biopharma: Vor Bio Announces $175 Million Private Placement

June 26, 2025 | finanznachrichten.de

Vor Biopharma: Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

June 26, 2025 | finanznachrichten.de

Vor Biopharma stock soars after licensing deal for autoimmune therapy

June 26, 2025 | investing.com

Wedbush Reaffirms "Neutral" Rating for Vor Biopharma (NYSE:VOR)

June 26, 2025 | marketbeat.com

Vor Bio Announces $175 Million Private Placement

June 25, 2025 | globenewswire.com

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

June 25, 2025 | globenewswire.com

Estimating The Fair Value Of Vor Biopharma Inc. (NASDAQ:VOR)

June 25, 2025 | finance.yahoo.com

Vor Biopharma Stock Price History - Investing.com

June 24, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

More Than a Monetary Metal: Silver's Case for Outperformance
By Jeffrey Neal Johnson | June 22, 2025
View More Than a Monetary Metal: Silver's Case for Outperformance
Which Analyst-Favorite Drone Stock Will Come Out on Top?
By Nathan Reiff | June 25, 2025
View Which Analyst-Favorite Drone Stock Will Come Out on Top?
Top Steel Picks for the Coming Infrastructure Boom
By Chris Markoch | June 25, 2025
View Top Steel Picks for the Coming Infrastructure Boom
3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
By Nathan Reiff | June 9, 2025
View 3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
Top 3 FOMO Stocks for 2025 With More Room to Run
By Dan Schmidt | June 9, 2025
View Top 3 FOMO Stocks for 2025 With More Room to Run

VOR, RNAC, CKPT, and TECX Company Descriptions

Checkpoint Therapeutics NASDAQ:CKPT

$4.26 0.00 (0.00%)

As of 05/30/2025

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Cartesian Therapeutics NASDAQ:RNAC

$10.39 -0.29 (-2.72%)

As of 06/30/2025 04:00 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Tectonic Therapeutic NASDAQ:TECX

$19.87 +0.07 (+0.35%)

As of 06/30/2025 04:00 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Vor Biopharma NYSE:VOR

$1.62 +0.56 (+52.83%)

As of 06/30/2025 04:00 PM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time